Content » Vol 90, Issue 5

Clinical Report

Hepatocellular Carcinoma in Variegate Porphyria: A Serious Complication

Xiaoye Schneider-Yin, Anne-Moon van Tuyll van Serooskerken, Philip Went, Wojciech Tyblewski, Pamela Poblete-Gutiérrez, Eliabeth I. Minder, Jorge Frank
DOI: 10.2340/00015555-0870


Variegate porphyria is an acute hepatic porphyria resulting from a partial deficiency of protoporphyrinogen oxidase, the penultimate enzyme in haem biosynthesis. Cutaneous symptoms and acute neurovisceral attacks are well-known clinical characteristics of the disease. Less studied, however, is the risk of developing hepatocellular carcinoma, an aggressive type of liver cancer. We describe here two Swiss patients with variegate porphyria and this serious complication. Common risk factors, including alcohol over-consumption or chronic hepatitis, were absent in both patients. Interestingly, one patient carried mutation 1082–1083insC in the PPOX gene, a prevalent sequence deviation in the Swiss variegate porphyria population, which was also found in a French patient with variegate porphyria and hepatocellular carcinoma. Recent studies indicate that individuals with acute hepatic porphyria have a 36- to 61-fold increased risk of manifesting hepatocellular carcinoma. The incidence rate ratio in the Swiss population was estimated to be 34, comparable with those found in the French and Finnish populations. Because this tumour is associated with a rising mortality, we suggest regular screening for hepatocellular carcinoma in all patients with variegate porphyria.


Supplementary content


Not logged in! You need to login/create an account to comment on articles. Click here to login/create an account.